Steatosis and hepatitis C;Steatosi ed epatopatia HCV correlata

Recenti Progressi in Medicina

Volumn 96, Issue 12, 2005, Pages 621-633

  Testino, Gianni ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Cirrhosis; Fibrosis; Hepatitis C virus; Hepatocellular carcinoma; Metabolic syndrome; Steatosis

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ANTIVIRUS AGENT; BETAINE; GEMFIBROZIL; INTERFERON; METFORMIN; PEGINTERFERON; PIOGLITAZONE; RIBAVIRIN; ROSIGLITAZONE; SILYMARIN; TROGLITAZONE; URSODEOXYCHOLIC ACID;

DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; HEPATITIS C; HEPATITIS C VIRUS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; REVIEW; STEATOSIS;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FATTY LIVER; HEPATITIS C; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; IRON OVERLOAD; LIVER CIRRHOSIS; LIVER NEOPLASMS; OXIDATIVE STRESS; RISK FACTORS;

EID: 30944431699     PISSN: 00341193     EISSN: 00341193     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. Brunt EM, Tiniakos DG. Steatosis, steatohepatitis: review of effects on chronic hepatitis C. Current Hepatitis Reports 2002; 1: 38-44.
2. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 2004; 126: 586-97.
3. Castera L, Chouteau P, Hezode C, Zafrani ES, Dhumeaux D, Pawlotsky JM. Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol 2005; 100: 711-15.
4. Loguercio C, De Girolamo V, De Sio I, Tucillo C, Ascione A, Baldi F. Non-alcoholic fatty liver disease in an area of Southern Italy: main clinical, histological and pathophysiological aspects. J Hepatol 2001; 35: 568-74.
5. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Parlotto A, Bozzola L, Smedile A, Negro F. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 2004; 53: 406-12.
6. Solis-Herruzo JA, Perez-Carreras M, Rivas E, Fernandez-Vazquez I, Garfia C, Bernardos E, Castellano G, Colina F. Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. Am J Gastroenterol 2005; 100: 1091-98.
7. Liu CJ, Jeng YM, Chen PJ, Lai MY, Yang HC, Huang WL, Kao JH, Chen DS. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. Antiviral Therapy 2005; 10: 405-15.
8. Hezode C, Roudot-Thoraval F, Zafrani ES, Dhumeaux D, Pawlotsky JM. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J of Viral Hepatitis 2004; 11: 455-58.
9. Asselah T, Boyer N, Marcellin P. Steatosis in hepatitis C: what does it mean ? Current Hepatitis Reports 2003; 2: 137-44.
10. Sanyal AJ, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Stravitz T, Mills S. Nonalcoholic fatty liver disease in patients with hepatitis C is associated of the metabolic syndrome. Am J Gastroenterol 2003; 98: 2064-71.
11. Diehl AM, Li ZP, Lin HZ, Yang SQ. Cytokines and the pathogenesis of non-alcoholic steatohepatitis. Gut 2005; 54: 303-06.
12. Kaser S, Moschen A, Cayon A, Kaser A, Crespo J, Pons-Romero F, Ebenbichler CF, Patsch JR, Tilg H. Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 2005; 54: 117-21.
13. Koike K, Moriya K. Metabolic aspects of hepatitis C viral infection: steatohepatitis resembling but distinct from NASH. J Gastroenterol 2005; 40: 329-36.
14. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-08.
15. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/P13-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003; 38: 1384-92.
16. Castera L, Hezode C, Roudot-Thoraval F, Lonjon I, Zafrani ES, Pawlotsky JM, Dhumeaux D. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 2004; 53: 420-24.
17. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, Heaton S, Conrad A, Pockros PJ, McHutchinson JG. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40: 484-90.
18. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002; 36: 1266-72.
19. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F. J Hepatol 2000; 33: 106-15.
20. Perlemuter G, Sabile A, Letteron P, Vona G, Topico A, Chretien Y, Koike K, Pessayre D, Chapman J, Barba G, Brechot C. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16: 185-94.
21. Ramesh S, Sanyal AJ. Hepatitis C and nonalcoholic fatty liver disease. Seminars in Liver Disease 2004; 24: 399-413.
22. Hezode C, Roudot-Thoraval F, Zafrani ES. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 2004; 11: 455-8.
23. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
24. Brunt EM. Nonalcoholic steatohepatitis. Seminars in Liver Disease 2004; 24: 1-19.
25. Alberti A, Chemello L, Benvegnù L. Natural history of hepatitis C. J Hepatol 1999; 31: 17-24.
26. Everson GT. Treatment of chronic hepatitis C in patients with decompensated cirrhosis. Reviews in Gastroenterological Disorders 2004; 4: S31-S38.
27. Afdhal NH. The natural history of hepatitis C. Seminars in Liver Disease 2004; 24: 3-8.
28. Poynard T. Treatment of cirrhotic patients in the pegylated Interferon era. Dig Liv Dis 2004; 36 (Suppl 3): S344-S348.
29. Pinzani M, Rombouts K. Liver fibrosis: from the bench to clinical targets. Dig Liv Dis 2004; 36: 231-242.
30. Fabris P, Floreani A, Carlotto A, Giordani MT, Baldo V, Stecca C, Marchioro L, Tramarin A, Bertin T, Negro F, de Lalla F. Alcohol is an important co-factor for both steatosis and fibrosis in Northern Italian patients with chronic hepatitis C. J Hepatol 2004; 41: 644-51.
31. Cholet F, Nousbaum JP, Richecoeur M, Oger E, Cauvin JM, Lagarde N, Robaszkiewicz M, Gouerou H. Gastroenterol Clin Biol 2004; 28: 272-8.
32. Takato U, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-7.
33. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR, Powell EE. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002; 51: 89-94.
34. Hickman IJ, Powell EE, Prins JB, Clouston AD, Ash S, Purdie DM, Jonsson JR. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 2003; 39: 1042-48.
35. Collier JD, Woodall T, Wight DGD, Shore S, Gimson AE, Alexander JM. Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection. J Viral Hepatitis 2005; 12: 74-80.
36. Farrell GC, George J, McCullough AJ. Fatty liver disease - NASH and related disorders. Blackwell Publishing, Oxford: 2005.
37. Clouston AD, Jonsson JR, Purdie DM, Macdonald GA, Pandeya N, Shorthouse C, Powell EE. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 2001; 34: 314-20.
38. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR. Fibrosis correlates with ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005; 41: 809-818.
39. Kitase A, Hino K, Furutani T, Okuda M, Gondo T, Hidaka I, Hara Y, Yamaguchi Y, Okita K. In situ detection of oxidized n-3 polynsaturated fatty acids in chronic hepatitis C: correlation with hepatic steatosis. J Gastroenterol 2005; 40: 617-24.
40. Falcon V, Acosta-Rivero N, Shibayama M, Chinea G, Gavilondo JV, de la Rosa MC. HCV core protein localizes in the nuclei of nonparenchimal liver cells from chronically HCV-infected patients. Biochem Biophys Res Commun 2005; 329: 1320-8.
41. Suzuki R, Sakamoto S, Tsutsumi T, Rikimaru A, Tanaka K, Shimoike T. Molecular determinants for subcellular localization of hepatitis C virus core protein. J Virol 2005; 79: 1271-81.
42. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114: 1752-61.
43. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 147: 147-52.
44. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radical Biology and Medicine 2003; 34: 1-10.
45. Higuchi H, Gores GJ. Mechanisms of liver injury: an overview. Current Molecular Medicine 2003; 3: 483-90.
46. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-75.
47. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemaster JJ. Mechanisms of Hepatotoxicity. Toxicological Sciences 2002; 65: 166-76.
48. Pinzani M, Romanelli RG, Magli S. Progression of fibrosis in chronic liver diseases: time to tally the score. J Hepatol 2001; 34: 764-67.
49. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
50. Castera L, Hezode C, Roudot-Thoraval, Bastie A, Zafrani ES, Pawlotsky JM, Dhumeaux D. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52: 288-92.
51. Zhang LH, Fu Ji J. Molecular profiling of hepatocellular carcinomas by cDNA microarray. World J Gastroenterol 2005; 11: 463-68.
52. Fattowich G, Stroffolini T, Zagni I, Donate F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50.
53. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Carcinogenesis 2001; 61: 4365-70.
54. Roskamas T, Yang SQ, Koteish A, Durnez A, DeVos R, Huang X. Oxidative stress and oval cell accumulation in mice and humans with alcoholic and non-alcoholic fatty liver disease. Am J Pathol 2003; 163: 1301-11.
55. Ohata K, Hamasaki K, Toriyama K, Matsumoto K, Saeki A, Yanagi K. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003; 97: 3036-43.
56. Harrison SA, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, Bacon BR. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2005; 3: 604-9.
57. Ijaz S, Yang W, Winslet MC, Seifalian AM. Impairment of hepatic microcirculation in fatty liver. Microcirculation 2003; 10: 447-56.
58. Poynard T, Ratziu V, McHutchinson J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38: 75-85.
59. Ferenci P. Predictors of response to therapy for chronic hepatitis C. Seminars in Liver Disease 2004; 24 (Suppl. 2): 25-31.
60. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 10 (Suppl. 1): S19-S27.
61. Machicao VI, Krishna M, Bonatti H, Aqel BA, Nguyen JH, Weigand SD, Rosser BG, Hughes C, Dickson R. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation. Liver Transpl 2004; 10: 599-606.
62. Gisbert C, Prieto M, Berenguer M, Breto M, Carrasco D, de Juan M, Mir J, Berenguer J. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg 1997; 3: 416-22.
63. Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I. Metabolic complications after liver transplantation. Transplantation 1995; 15: 1057-60.
64. Ansaldi F, Bruzzone B, Testino G, Bassetti M, Gasparini R, Crovari P, Icardi G. Combination hepatitis C virus antigen and antibody immunoassay as a new tool for early diagnosis of infection. Journal of Viral Hepatitis 2005; in press.
65. Testino G., Icardi G. Hepatocellular carcinoma and Interferon therapy in HCV compensated cirrhosis: evaluation in relation to virological response. Hepato-Gastroenterology 2005; 52: IX.
66. Testino G, Ansaldi F, Andorno E, Ravetti GL, Ferro C, De Iaco F, Icardi GC, Valente U. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis. Hepato-Gastroenterology 2002; 49: 1636-38.
67. Andy SY, Emmet B, Keeffe EB. Nonalcoholic fatty liver disease. Reviews in Gastroenterological disorders 2002; 2: 11-19.
68. Oneta CM, Dufour JF. Nonalcoholic fatty liver disease: treatment options based on pathogenic considerations. Swiss Med WKLD 2002; 132: 493-505.
69. Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial. Aliment Pharmacol Ther 2004; 20: 23-8.
70. Nammour FE, Fayad NF, Peikin SR. Metformin-induced cholestatic hepatitis. Endocr Pract 2003; 9: 307-9.
71. Kohlroser J, Mathai J, Reichheld J, Banner BF, Bonkovsky HL. Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am J Gastroenterol 2000; 95: 272-6.
72. Manon KVN, Angulo P, Lindor KD. Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabete mellitus. Am J Gastroenterol 2001; 96: 1631-4.
73. Al-Salmar J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Int Med 2000; 132: 121-4.
74. May LD, Lefkowitch JH, Kram MT, Rubin DE. Mixed hepatocellular- cholestatic liver injury after pioglitazone therapy. Ann Int Med 2002; 136: 449-52.
75. Laurin J, Lindor KD, Crippin JS. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23: 1464-67.
76. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. J Hepatol 1999; 31: 384.
77. Apostolos H, Christos S, Georgia L, Ionnis S, Persefoni H, Anastasios L, Valentini T, Koliouskas D. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol 2004; 23: 131-134.
78. Lavine JE. Vitamin E treatment of non-alcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136: 734-8.
79. Hasegawa T, Yoneda M, Nakamura K. Plasma transforming growth factor-b1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study. Aliment Pharmacol Ther 2001; 15: 1667-72.
80. Lyn P. Nonalcoholic fatty liver disease: relationship to insulin sensitività and oxidative stress. Treatment approaches using vitamin E, magnesium, and betaine. Alternative Medicine Review 2002; 7: 276-291.
81. Pietrangelo A, Borella F, Casalgrandi G, Montorsi G, Ceccarelli D, Gallesi D, Giovannini F, Gasparetto A, Masini A. Antioxidant activity of silybin in vivo durino long-term iron overload in rats. Gastroenterology 1995; 109: 1941-9.
82. Neuman MG, Cameron RG, Haber JA, Katz GG, Malkiewicz IM, Shear NH. Inducers of cytochrome P450 2E1 enhance methotrexate-induced hepatocytoxicity. Clin Biochem 1999; 32: 519-36.
83. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Bocker RH, Beckurts KT, Lang W, Hunz M, Fuhr U. Inhibitory effects of sibilin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000; 86: 250-6.
84. Trappoliere M, Federico C, Tuccillo C, de Sio I, Di Leva A, Niosi M, D'Auria M, Loguercio C. Effects of new pharmacological complex (sylibin + vitamin E + phospholipids) on some markers of metabolic syndrome and of a liver fibrosis in patients with non-alcoholic fatty liver disease: a preliminary open pilot study. Minerva Gastroenterol Dietol 2005; 51: 193-9.
85. Jeong DH, Lee GP, Jeong WI, Do SH, Yang HJ, Yuan DW, Kim KJ, Jeong KS. Alterations of mast cells and TGF-beta 1 on the silymarin treatment for CCl(4)-induced hepatic fibrosis. World J Gastroenterol 2005; 28: 1141-8.
86. Katiuyar SK, Roy AM, Baliga MS. Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome C release, and capsase activation. Mol Cancer Ther 2005; 4: 207-16.
87. Strickland GT, Tanamly MD, Tadros F, Labeeb S, Makld H, Nessim D. Two-year results of a randomized double-blinded trial evaluating silymarin for chronic hepatitis C. Dig Liv Dis 2005; 37: 542-43.
88. Mahmood S, Kawanaka M, Kamei A, Izumi A, Nakata K, Njiyama G. Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C. Antioxidants and Redox Signaling 2004; 6: 19-24.
89. Cammà C, Di Marco V. Long-term course of Interferon-treated chronic hepatitis C. J Hepatol 1998; 28: 531-37.
90. Perasso A, Testino G, Ansaldi F, Venturino V, Icardi GC. Interferon alfa-2b/ Ribavirin and therapy followed by low-dose r-Interferon alfa-2b in chronic hepatitis C Interferon non-responders. Hepatology 1999; 29: 296-97.
91. Testino G, Ansaldi F. Interferon therapy in chronic hepatitis C virus in the prevention of worsening independently of ALT response: is it conceivable? Hepato-Gastroenterology 2001; 48: VIII.
92. Baker DE. Pegylated Interferon plus Ribavirin for the treatment of chronic hepatitis C. Reviews in Gastroenterological Disorders 2003; 3: 93-109.
93. Lee WL, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML and the HALT-C Trial Group. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Controlled Clinical Trials 2004; 25: 472-92.
94. Craxi A, Cammà C. Prevention of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 329-46.
95. Marrache F, Consigny Y, Ripault MP, Cazals-Hatem D, Martinet M, Marcellin P. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis and brindging fibrosis or cirrhosis. J Viral Hepat 2005; 12: 421-8.
96. Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. Hepatology 2005; 42: 5-13.
97. Sumberaz A, Mattioli F, Grossi S, Garbero C, Testino G, Martelli A. DNA fragmentation in human lymphocytes in alcoholic and post-viral cirrhosis. XIV Congresso Nazionale della Società Italiana di Tossicologia, 2006.
98. Koike K. Hepatitis C virus infection can present with metabolic disease by inducing insulin resistance. Intervirology 2006; 49: 51-7.
99. Bataller R, Sancho-Bru P, Gines P, Brenner DA. Liver fibrogenesis. Antioxidant and Redox Signaling 2005; 7: 1346-55.
100. Gasbarrini G, Vero V, Miele L, Greco AC, Gasbarrini A, Greco A. Nonalcoholic fatty liver disease: defining a common problem. Eur Rev Med Pharmacol Sci 2005; 9: 251-2.
101. Trappoliere M, Tuccillo C, Federico A, Coppola F, D'Auria M, Loguercio C. The treatment of NAFDL. Eur Rev Med Pharmacol Sci 2005; 9: 299-304.
102. Melhem A, Stern M, Shibolet O, Zabrecky G, Cohen R, Ilan Y. Treatment of chronic hepatitis C virus infection via antioxidants: results of a phase I clinical trial. J Clin Gastroenterol 2005; 39: 737-42.